A new generation of weight-loss drugs has proven remarkably effective, hugely popular and massively lucrative in the last few ...

Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday. Verve is developing ...

Analysts say Wegovy, a once-a-week injection, had been priced competitively to Mounjaro in India, and that is likely to ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly’s revenue has grown at an average annual rate of 17.4% over the past three years (vs. 6.2% for the S&P 500) Revenue rose 32.0% from $34 billion to $45 billion over the past year (vs. 5 ...

Lilly’s phase 3 trial showed that type 2 diabetes patients lost 16 pounds, or nearly 8 per cent of their body weight, over 40 weeks. That compares favourably with Novo’s injected drug Ozempic ...

Eli Lilly, the drugmaker behind the blockbuster weight loss drug Zepbound, is suing four telehealth companies for allegedly selling illegal copies of the drug made by compounding pharmacies ...